Fimbrion Therapeutics, Inc.
Publicly observedSaint Louis, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Saint Louis | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Fimbrion Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | N9RQX3G4EH54 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant9 Sept 2025Publicly observed
NIH SBIR/STTR award: Thiazolino-Pyridone Compounds as Novel Antimycobacterial Drugs for Tuberculosis
USD 300,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant9 Sept 2025Publicly observed
NIH SBIR/STTR award: Thiazolino-Pyridone Compounds as Novel Antimycobacterial Drugs for Tuberculosis
USD 300,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Aug 2025Publicly observed
NIH SBIR/STTR award: Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas Infections
USD 300,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Aug 2025Publicly observed
NIH SBIR/STTR award: Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas Infections
USD 300,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant23 Jul 2025Publicly observed
NIH SBIR/STTR award: Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria
USD 300,001.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant23 Jul 2025Publicly observed
NIH SBIR/STTR award: Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria
USD 300,001.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.